Replimune Group, Inc.
RP2
metastatic uveal melanoma
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for RP2 in metastatic uveal melanoma are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling.”